A20 mRNA therapeutics ameliorate systemic sclerosis by suppressing TRAF-6/NF-KB signaling and DREAM expression and exerting antifibrotic effects.
Saved in:
| Title: | A20 mRNA therapeutics ameliorate systemic sclerosis by suppressing TRAF-6/NF-KB signaling and DREAM expression and exerting antifibrotic effects. |
|---|---|
| Authors: | Lee AR; Lab of Translational ImmunoMedicine, Catholic Research Institute of Medical Science, College of Medicine, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.; Department of Pathology, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea., Jeon SB; Lab of Translational ImmunoMedicine, Catholic Research Institute of Medical Science, College of Medicine, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.; Department of Pathology, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.; Department of Medical Sciences, Graduate School of The Catholic University of Korea, Seoul, Republic of Korea., Kwak HW; SML Biopharm, Gwanmyeong-si, Gyeonggi-do, Republic of Korea., Yang SW; Lab of Translational ImmunoMedicine, Catholic Research Institute of Medical Science, College of Medicine, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea., Bang YJ; SML Biopharm, Gwanmyeong-si, Gyeonggi-do, Republic of Korea., Lee SY; Lab of Translational ImmunoMedicine, Catholic Research Institute of Medical Science, College of Medicine, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.; Department of Pathology, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea., Lee SW; Department of Medical and Biological Sciences, The Catholic University of Korea, Bucheon, Republic of Korea.; BK21 Four, Department of Biotechnology, The Catholic University of Korea, Bucheon, Gyeonggi-do, Republic of Korea., Park JH; Lab of Translational ImmunoMedicine, Catholic Research Institute of Medical Science, College of Medicine, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.; Department of Pathology, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.; Department of Medical Sciences, Graduate School of The Catholic University of Korea, Seoul, Republic of Korea., Han SG; Lab of Translational ImmunoMedicine, Catholic Research Institute of Medical Science, College of Medicine, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.; Department of Pathology, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.; Department of Medical Sciences, Graduate School of The Catholic University of Korea, Seoul, Republic of Korea., Choi JW; Lab of Translational ImmunoMedicine, Catholic Research Institute of Medical Science, College of Medicine, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.; Department of Pathology, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.; Department of Medical Sciences, Graduate School of The Catholic University of Korea, Seoul, Republic of Korea., Park HJ; Department of Medical and Biological Sciences, The Catholic University of Korea, Bucheon, Republic of Korea.; BK21 Four, Department of Biotechnology, The Catholic University of Korea, Bucheon, Gyeonggi-do, Republic of Korea., Cho ML; Lab of Translational ImmunoMedicine, Catholic Research Institute of Medical Science, College of Medicine, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.; Department of Pathology, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.; Department of Medical Sciences, Graduate School of The Catholic University of Korea, Seoul, Republic of Korea., Nam JH; SML Biopharm, Gwanmyeong-si, Gyeonggi-do, Republic of Korea.; Department of Medical and Biological Sciences, The Catholic University of Korea, Bucheon, Republic of Korea. |
| Source: | Frontiers in immunology [Front Immunol] 2025 Oct 16; Vol. 16, pp. 1665998. Date of Electronic Publication: 2025 Oct 16 (Print Publication: 2025). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
